biostudies-literatureDu YXi'an medical key project for science and technologyTangdu hospital discipline promotion projectShaanxi Innovative Team for Science and TechnologyTangdu hospital foundation for social recruitment talentNational Natural Science Foundation of ChinaTangdu hospital clinical research projectthe National Natural Science Foundation of ChinaTangdu hospital innovation development foundationShaanxi Province Health Research and Innovation Team for Cognitive Dysfunction Disease180-191https://www.ebi.ac.uk/biostudies/studies/S-EPMC11752089biostudies-literatureUnknown12(1)<h4>Objective</h4>To determine the efficacy and safety of combined low-dose rituximab with conventional therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment.<h4>Methods</h4>Total 73 patients with CIDP were enrolled for the retrospective cohort study, and divided into conventional first-line therapy cohort (n = 40) and combined low-dose rituximab (100 mg per infusion) cohort (n = 33). The outcome measures include scores of I-RODS, mRS, INCAT, ONLS, TSS, and COMPASS 31 scale at baseline and regular four visits (4, 16, 28, and 52 weeks), as well as proportion of favorable response and outcome, corticosteroids dosage, and deterioration occurrence during follow-up.<h4>Results</h4>Compared to conventional therapy cohort, combined rituximab cohort presented betteAnnals of clinical and translational neurologyEfficacy and safety of combined low-dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy.PMC117520892024JCRH0222023TD-062021SHRC0112024RS-CXTD-872024JH-YXZD-00472021LCYJ0402018QYTS01082171406822714572019QYTS002Liu JHan LHou TDu YHao YLiu SZhang RZhao YJiang PWang PDang YWang YLi HLi JYan QLi CZhao CChen FLi LZhou XZhang WLi YGao LYao DZhu WZhu TfalseEfficacy and safety of combined low-dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy.<h4>Objective</h4>To determine the efficacy and safety of combined low-dose rituximab with conventional therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment.<h4>Methods</h4>Total 73 patients with CIDP were enrolled for the retrospective cohort study, and divided into conventional first-line therapy cohort (n = 40) and combined low-dose rituximab (100 mg per infusion) cohort (n = 33). The outcome measures include scores of I-RODS, mRS, INCAT, ONLS, TSS, and COMPASS 31 scale at baseline and regular four visits (4, 16, 28, and 52 weeks), as well as proportion of favorable response and outcome, corticosteroids dosage, and deterioration occurrence during follow-up.<h4>Results</h4>Compared to conventional therapy cohort, combined rituximab cohort presented bette2025-01-01T00:00:00Z2025 Jan2025-04-05T11:35:26.766Z2025-04-05T11:35:26.766ZS-EPMC117520893966053510.1002/acn3.52270